In vitro activity of quinupristin/dalfopristin against selected bacterial pathogens isolated in Italy

Clinical Microbiology and Infection

Volumn 5, Issue 8, 1999, Pages 488-495

  Marchese, Anna ^a   Debbia, Eugenio A ^a   Schito, Gian Carlo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Gram positive pathogens; In vitro activity; Italian isolates; Quinupristin dalfopristin

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GLYCOPEPTIDE; OXACILLIN; STREPTOGRAMIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNICABLE DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; ITALY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SANGUINIS;

EID: 0032877139     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00178.x     Document Type: Article

References (39)

1. Gold HS, Moellering Jr RC. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445-53.
2. Segal-Maurer S, Urban C, Rahal Jr JR. Current perspectives on multidrug-resistant bacteria: epidemiology and control. Infect Dis Clin North Am 1996; 10: 939-57.
3. O'Brien TF. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis 1997; 24(suppl 1): S2-8.
4. Levy SB. Multidrug resistance - a sign of the times. N Engl J Med 1998; 338: 1376-8.
5. Vincent JL, Blhari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995; 274: 639-44.
6. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
7. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-7.
8. Schito GC, Pesce A, Marchese A. The role of macrolides in Streptococcus pyogenes pharyngitis. J Antimicrob Chemother 1997; 39: 562-5.
9. Doern GV, Ferraro MJ, Brueggemenn AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in United States. Antimicrob Agents Chemother 1996; 40: 891-4.
10. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24(suppl 1); S85-8.
11. Doern GV, the Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38(suppl A): 59-69.
12. Berk SL, Kalbfleisch JH, the Alexander Project Collaborative Group. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA. J Antimicrob Chemother 1996; 38(suppl A): 85-96.
13. Shonekan D, Handwerger S, Mildvan D. Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. J Antimicrob Chemother 1997; 39: 405-9.
14. Bouanchaud DH. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother 1997; 39(suppl A): 15-21.
15. Finch RG. Antibacterial activity of quinupristin/dalfopristin, rationale for clinical use. Drugs 1996, 51(suppl 1): 31-7.
16. Pradier C, Dunais B, Carsenti-Etesse H, Dellamonica P. Pneumococcal resistance patterns in Europe. Eur J Clin Microbiol Infect Dis 1997; 16: 644-7.
17. Mazzaglia G, Greco S, Lando C, Cucinotta G, Caputi AP. Adult acute upper respiratory tract infections in Sicily: pattern of antibiotic drug prescription in primary care. J Antimicrob Chemother 1998; 41: 259-66.
18. Marchese A, Debbia EA, Pesce A, Schito GC. Comparative activity of amoxycillin and ten other oral drugs against penicillin susceptible and resistant Streptococcus pneumoniae strains recently isolated in Italy. Clin Microbiol Infect 1998; 4: 170-3.
19. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th edn. Approved standard M7-A4. Villanova: PA: NCCLS, 1997.
20. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Villanova, Pa: NCCLS, 1995.
21. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994, 13: 50-5.
22. Schito GC, Varaldo P. Trends in the epidemiology and antibiotic resistance of clinical Staphylococcus strains in Italy - a review. J Antimicrob Chemother 1988; 21(suppl C): 67-78.
23. Schito GC, Debbia EA, Pesce A, The Alexander Project Collaborative Group. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992-1993). J Antimicrob Chemother 1996; 38(suppl A): 97-106.
24. Marchese A, Debbia EA, Bacca D, Balistreri G. Musolino B, Schito GC. Multidrug-resistant gram-positive pathogens: an update on current microbiological patterns. Drugs 1997; 54(suppl 6): 11-20.
25. Hill RLR, Smith CT, Seyed-Akhavani M, Casewell MW. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamycin-resistant Enterococcus faecium. J Antimicrob Chemother 1997; 39(suppl A): 23-8.
26. Bisno AL, Gerber MA, Gwaltney Jr JM, Kaplan EL, Schwartz RH. Diagnosis and management of group A streptococcal pharyngitis: a practical guideline. Clin Infect Dis 1997; 25: 574-83.
27. Cornaglia G, Ligozzi M, Mazzariol A, et al. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. Emerg Infect Dis 1996; 2: 339-42.
28. Chelossi E, Platè M, DeLeo C, Schito GC. Attività di alcuni antibiotici su Streptococcus pyogenes isolati recentemente in Italia. G Ital Microbiol Med Odontoiatr Clin 1997; 1: 7-21.
29. Borzani M, DeLuca M, Varotto F. A survey of susceptibility to erythromycin amongst Streptococcus pyogenes isolates in Italy. J Antimicrob Chemother 1997; 40: 457-8.
30. Nakae M, Murai T, Kaneko Y, Mitsuhashi S. Drug resistance in Streptococcus pyogenes isolated in Japan. Antimicrob Agents Chemother 1997: 12: 427-8.
31. File TM, Tan JS, Plouffe JF. Community-acquired pneumonia. Postgrad Med 1996; 99: 95-107.
32. Pallares R, Linares J, Vadillo M. et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumoniae in Barcelona, Spain. N Engl J Med 1995; 333: 474-80.
33. Carratalà J, Marron A, Fernandez-Sevilla A, Liñares J, Gudiol F. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1996; 24: 148-52.
34. Paris MM, Ranilo O, McCracken Jr G. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 39: 2171-5.
35. Goldstein FW, Garau J. 30 years of penicillin-resistant Streptococcus pneumoniae: myth or reality? Lancet 1997; 350: 233-4.
36. Tarasi A, Dever LL, Tomasz A. Activity of quinupristin/ dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis. J Antimicrob Chemother 1997; 39(suppl A): 121-7.
37. Barry AL, Fuchs PC, Brown SD. Provisional interpretative criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother 1997; 39(suppl A): 87-92.
38. Tenover FC, Baker CN. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin. J Antimicrob Chemother 1997; 39(suppl A): 81-5.
39. Seppälä H, Nissinen A, Yu Q, Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993; 32: 885-91.